New prostate cancer screening guidelines
The American Cancer Society (ACS) announced a major change in prostate cancer screening recommendations 11/12/2026, its first update since 2010.
The ACS now recommends routine PSA blood testing, rather than primarily recommending that men decide whether to undergo screening after discussing it with their physician.
New PSA screening recommendations
Population | Starting age | Frequency |
Average-risk men | 50 | Every 2 years through age 69 |
Black men | 45 | Annually through age 69 |
Strong family history* | 45 | Annually through age 69 |
One first-degree relative diagnosed at age 65 or older (non-Black men) | 45 | Every 2 years through age 69 |
Men ages 70–74 | Individualized | Shared decision-making |
Men 75 and older | Generally not recommended | Exceptions for selected very healthy men ages 75–79 |
Strong family history means a first-degree relative diagnosed before 65, or multiple first-degree relatives diagnosed at any age
An elevated PSA doesn't automatically mean a patient needs a biopsy. Will possibly need additional PSA test, MRI and biomarkers to help reduce unnecessary biopsies and overdiagnosis
The evidence supporting PSA screening has strengthened. For example, the European Randomized Study of Screening for Prostate Cancer reported approximately a 20% relative reduction in prostate cancer mortality at 16 years among men invited to screening.


Comments